In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.
Cystic renal cell carcinoma is a predominantly cystic lesion with a small solid component (25% or less). Renal cell carcinoma usually presents as a solid mass; however, in 10–22% of cases ...
Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...
Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ...
At this year’s ASCO Annual Meeting, researchers presented detailed findings concerning biomarkers and rare subtypes of renal ...
Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...
News Medical on MSN4d
Neoantigen vaccine sparks powerful immune defense against kidney cancerA personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...
A neoantigen-targeting personalized cancer vaccine may be effective as adjuvant therapy in patients with high-risk clear cell renal cell carcinoma, phase 1 data suggest.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback